Site for AALL1732:: A Phase 3 Randomized Trial of Inotuzumab Ozogamicin (IND#:133494 NSC#: 772518) for Newly Diagnosed High-Risk B-ALL; Risk Adapted Post-Induction Therapy for High-Risk B-ALL Mixed Phenotype Acute Leukemia and Disseminated B-LLy

Are you eligible to participate in this study?

You may be eligible for this study if you meet the following criteria:

  • Conditions:
    B-lly; Mpal
  • Age: Between 1 Year(s) - 24 Year(s)
  • Gender: Male or Female
  • Other Inclusion Criteria:
    1) White blood cell count (WBC) criteria for patients with B-ALL (within 7 days prior to the start of protocol-directed systemic therapy): ?Age 1-9.99 years: WBC >= 50,000/uL ?Age 10-24.99 years: Any WBC ?Age 1-9.99 years: WBC < 50,000/uL with: ?Testicula

You may not be eligible for this study if the following are true:

  • 1) Patients with Down Syndrome are not eligible. 2) Patients with known Charcot-Marie-Tooth disease. 3) Patients with Acute Undifferentiated Leukemia (AUL) are not eligible.

If you are registered as a volunteer, please log in to contact the study team/express interest in this study.

Contact the research team to learn more about this study.

By clicking "Contact Research Team", your contact information will be sent securely to the research staff associated with the study. You will also receive a copy of this email in your inbox, as well as other notifications to determine your participation status in the study.